SEC Form 4 · accession 0001104659-18-017201
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen L Sabba
Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 13, 2018 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 12, 2018 | S | 622 | $180.73 | D | 26,363 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These securities, as represented in Column 5, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.